

1 **Sensorineural hearing impairment among preterm children**  
2 **- a Norwegian population-based study**

3 Dagny Hemmingsen <sup>a,b\*</sup>, Dag Moster<sup>c, d</sup>, Bo Lars Engdahl<sup>e</sup>, Claus Klingenberg <sup>b,f</sup>

4  
5 **Affiliations (all in Norway):**

6 <sup>a</sup> Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital of  
7 North Norway, Tromsø

8 <sup>b</sup> Research Group Child and Adolescent Health, Faculty of Health Sciences, UiT-The Arctic  
9 University of Norway, Tromsø

10 <sup>c</sup> Department of Global Public Health and Primary Care, University of Bergen, Bergen

11 <sup>d</sup> Department of Pediatrics, Haukeland University Hospital, Bergen

12 <sup>e</sup> Department of Physical Health and Ageing, Norwegian Institute of Public Health, Oslo

13 <sup>f</sup> Department of Paediatrics and Adolescence Medicine, University Hospital of North Norway,  
14 Tromsø

15

16 **Corresponding author:** Dagny Hemmingsen, Dept. of Otorhinolaryngology, University  
17 Hospital of North Norway, N-9038 Tromsø, Norway. Phone +47 77626000

18 Email: [dagny.e.hemmingsen@uit.no](mailto:dagny.e.hemmingsen@uit.no)

19

20 **Total words in abstract:** 249

21 **Total words in the main text of the paper:** 2534

22 **Number of tables:** 3

23 **Number of Figures:** 2

24 **Number of text boxes:** 3

25 **Number of references:** 41

26 **Keywords:** Hearing impairment, sensory loss, preterm, neonatal, morbidities

27

28 **Short title:** Risk for hearing impairment in preterm children

29

30

31 **Abstract**

32 **Objective:** To investigate the risk for sensorineural hearing impairment (SNHI) in preterm  
33 infants, and to what extent the risk is attributed to perinatal morbidities and therapies.

34 **Design:** Population-based cohort study using data from several nationwide registries.

35 **Setting:** Norwegian birth cohort 1999-2014, with data on SNHI until 2019.

36 **Participants:** 60 023 live-born preterm infants, divided in moderate-late preterm (MLP)  
37 infants (32-36 weeks), very preterm (VP) infants (28-31 weeks) and extremely preterm (EP)  
38 infants (22-27 weeks), and a reference group with all 869 797 term-born infants from the  
39 study period.

40 **Main outcome measures:** SNHI defined by selected ICD-10 codes, recorded during  
41 minimum five years observation period after birth.

42 **Results:** The overall SNHI prevalence in the preterm cohort was 1.4% compared to 0.7% in  
43 the reference group. The adjusted risk ratios (95% confidence intervals) for SNHI were 1.7  
44 (1.5-1.8) in MLP-infants, 3.3 (2.8-3.9) in VP-infants and 7.6 (6.3-9.1) in EP-infants. Among  
45 EP-infants, decreasing gestational age was associated with a steep increase in the risk ratio of  
46 SNHI reaching 14.8 (7.7-28.7) if born at 22-23 weeks gestation. Among the VP- and MLP-  
47 infants, mechanical ventilation and antibiotic therapy had strongest association with increased  
48 risk of SNHI, but infants not receiving these therapies remained at increased risk. Among EP-  
49 infants intracranial haemorrhage increased the already high risk for SNHI. We found no signs  
50 of delayed or late-onset SNHI in preterm infants.

51 **Conclusion:** Preterm birth is an independent risk factor for SNHI. Invasive therapies and co-  
52 morbidities increase the risk, predominantly in infants born after 28 weeks gestation.

53

54

55

56 **What is already known on this topic?**

- 57 • Preterm infants are at higher risk for hearing impairment than infants born at term.
- 58 • Many of the perinatal morbidities associated with preterm birth and their treatments are
- 59 also identified as separate risk factors for hearing impairment.
- 60 • To what extent the risk for hearing impairment in the preterm population is associated
- 61 with preterm birth itself, or by associated perinatal morbidity, is poorly clarified.

62

63 **What this study adds?**

- 64 • The risk for SNHI increased with decreasing gestational age, and most markedly among
- 65 the most immature infants born before 28 weeks of gestation.
- 66 • Invasive therapies and co-morbidities increased the risk for SNHI, but predominantly in
- 67 preterm infants born after 28 weeks gestation.

68

69 **How this study might affect research, practice, or policy**

- 70 • Early identification of hearing impairment in preterm infants is important for hearing
- 71 habilitation in this vulnerable group.
- 72 • Increased awareness and information on the risk for hearing impairment in extremely
- 73 preterm infants is important when counselling parents and for audiological surveillance
- 74 programs.

75

76

77

78

## 79 **Introduction**

80 Children born preterm are at increased risk for hearing impairment, a major and permanent  
81 disabling condition.<sup>1,2</sup> Early identification of childhood hearing impairment is of great  
82 importance for speech and language outcome.<sup>3,4</sup> Thus, a better understanding of the risks of  
83 hearing impairment in preterm infants can aid early identification and hearing habilitation in  
84 this vulnerable population.

85         Reported prevalence of hearing impairment in preterm infants varies between  
86 studies.<sup>5-8</sup> As for most neurodevelopmental outcomes, the prevalence seems to increase with  
87 decreasing gestational age<sup>5,7</sup>, but many studies have focused only on extremely preterm  
88 infants.<sup>6,9,10</sup> To what extent more moderate preterm birth represent an independent risk factor  
89 for hearing impairment, or if the risk is caused by other perinatal morbidities or treatments  
90 associated with preterm birth, is not well clarified. Several studies report that preterm infants  
91 with hearing impairment had more extensive intensive care treatment than those without,  
92 which could imply that cumulative and co-incident risk factors are more important than  
93 individual ones.<sup>11,12</sup>

94         To confirm a hearing impairment diagnosis in a preterm infant is diagnostically  
95 challenging. Newborn hearing screening test are less specific in preterm versus term born  
96 infants.<sup>13,14</sup> Auditory function in preterm infants is also reported to be more unstable and may  
97 both improve and deteriorate after the newborn period.<sup>6,15-19</sup> It is therefore essential to have  
98 long-term data on hearing outcomes when assessing risk for hearing impairment in preterm  
99 children.

100         In this study we evaluate the risk for sensorineural hearing impairment (SNHI) in a  
101 Norwegian population-based cohort of preterm infants born between 1999 and 2014. We used  
102 national patient registry data, with access to SNHI-diagnoses recorded during minimum five  
103 years observation period after birth.

## 104 **Methods**

### 105 **Data sources, linkage, and ethical approval**

106 Data for this study was obtained from five compulsory Norwegian national health and social  
107 registries. All registries were updated through 2019 and the unique 11-digit personal  
108 identification number from the mother and the infant was used to link data between registers.  
109 The Medical Birth Registry of Norway (MBRN) contains prospectively collected data on  
110 pregnancy, delivery, maternal and neonatal health.<sup>20,21</sup> The Norwegian Patient Registry (NPR),  
111 established in 2008, contains diagnoses (International Classification of Diseases, 10<sup>th</sup>  
112 Revision-ICD-10) reported from both public and private health care providers.  
113 Reimbursement for both inpatient and outpatient care is based on automatic reports of  
114 diagnostic and procedural codes to the NPR, leading to high completeness of data. The  
115 Norwegian National Insurance Scheme (NIS) is the public social security system in Norway  
116 and provides financial compensation for illness-related expenses, without regard to wealth or  
117 income. Everyone with diagnoses, including hearing impairment, entitled to financial support  
118 is recorded in NIS with ICD codes. The Norwegian Cause of Death registry include data for  
119 time and cause of death and Statistics Norway contains data on education and immigration  
120 status for parents. The current study was approved by the Regional Ethical Committee for  
121 medical and health research ethics (REK nr. 2018/1789).

### 122 **Study population**

123 We included all live-born infants in Norway over the 16-year period from January 1999 to  
124 December 2014. Gestational age (GA) was determined by foetal ultrasound data, routinely  
125 recorded in MBRN, or if not available by data on last menstrual period. We excluded children  
126 with a birth weight Z-score for GA outside 3SD or without available 11-digit personal  
127 identification number. To ensure sufficient follow-up time for a diagnosis of hearing  
128 impairment we also excluded children who died before 2 years age (Suppl. Figure 1). All

129 term-born infants ( $GA \geq 37$  weeks), including those who had been admitted a neonatal unit for  
130 treatment, constituted the reference population.

### 131 **Outcomes and definitions**

132 The main outcome was SNHI defined by selected ICD-10 codes registered in either the NPR  
133 (H90.3-5) or the NIS. To avoid potential false positive cases, a diagnosis of SNHI had to be  
134 recorded minimum twice in the NPR to be registered as a SNHI-case. From the NIS we  
135 included a broader range of ICD-10 codes for hearing impairment, including those for  
136 conductive, mixed, and unspecified hearing loss. This was done because explorative analysis  
137 of ICD-10 diagnoses for hearing impairment registered in the NIS revealed that most codes  
138 for hearing impairment were coded as “unspecific”, probably reflecting a focus on the degree  
139 of disability and not diagnostic code accuracy. Information on the diagnostics methods used to  
140 detect SNHI was not included in NPR/NIS. However, based on common clinical practice and  
141 guidelines<sup>22</sup>, it is reasonable to assume that brain stem audiometry was used in infants and  
142 toddlers, and pure tone audiometry in older children. Universal newborn hearing screening  
143 was implemented in Norway in 2008, and hearing is also assessed regularly in all Norwegian  
144 children during visits at public child health clinics. A complete list of the ICD-10 diagnoses  
145 for hearing impairment, and the number of cases included from the NPR and the NIS, is  
146 presented in Supplementary Table 1.

### 147 **Exposures, confounders, mediators, and covariates**

148 The main exposure of interest in this study was preterm birth, mainly subclassified in the  
149 following three groups: i) moderate-late preterm (MLP) infants ( $GA$  32-36 weeks), ii) very  
150 preterm (VP) infants ( $GA$  28-31 weeks) and iii) extremely preterm (EP) infants ( $GA$  22-27  
151 weeks). We included variables defined as confounders, mediators, and covariates. The  
152 maternal variables were daily smoking early in pregnancy, immigrant status, parental  
153 consanguinity, educational level, mode of delivery and prolonged ( $> 24$  hours) rupture of

154 membranes (PROM). Neonatal variables included sex, birth weight (BW) and length, small  
155 for GA (SGA) defined as birthweight < 10 percentile, antibiotic therapy, intracranial  
156 haemorrhage, jaundice therapy, non-invasive respiratory support, and mechanical ventilation.

### 157 **Statistical analysis**

158 All statistical analyses were performed using the SPSS software (28.0.1.0). Results are  
159 presented as proportions, means with standard deviations (SD) or medians with interquartile  
160 range (IQR), as appropriate. Comparisons of groups were performed with chi-square and non-  
161 parametric tests. Two-tailed P-values < 0.05 were considered statistically significant.

162 To evaluate the association between SNHI and the exposure groups of interest we used log-  
163 binomial regression analysis. Based on the literature, we identified possible confounders and  
164 mediators<sup>23,24</sup> and drew a directed acyclic graph (DAG) (Suppl. Figure 2). Foetal growth  
165 restriction was considered a possible confounder. Antibiotic therapy (as a proxy for a possible  
166 infection and/or ototoxic effects), intracranial haemorrhage, jaundice therapy, non-invasive  
167 respiratory support and mechanical ventilation were considered as mediators. To evaluate  
168 whether the associations between mediators, covariates and SNHI vary by the degree of  
169 prematurity, we performed stratified univariable log-binomial regression analyses within all  
170 subgroups. Then we performed log-binomial regression analysis in two steps, with adjustment  
171 for SGA in the second step. We did not perform a formal mediation analysis as we identified  
172 strong interactions between the exposure and mediators (Suppl. Table 2), and because the  
173 effect of mediators varied substantially between all subgroups. We present crude and adjusted  
174 risk ratios (aRR) with 95% confidence interval (CI).

175

176

177

178

179 **Results**

180 During the 16-year study period we included 60 023 preterm infants (53% male) and a  
181 reference group with 869 797 term-born infants (51.2% male). In the preterm cohort, 3.4%  
182 (n=2 065) were EP-infants, 10.3% (n= 6 192) were VP-infants and 86.3% (n=51 766) were  
183 MLP-infants. Table 1 displays maternal and infant characteristics according to the three main  
184 groups of preterm birth and the reference group. Rates of mechanical ventilation, antibiotic  
185 treatment and intracranial haemorrhage markedly increased with decreasing GA.

186 The SNHI-prevalence in the term reference group, including infants admitted to  
187 neonatal units for variable reasons, was 0.7%. In the cohort of preterm infants, the overall  
188 SNHI- prevalence was 1.4%. The prevalence increased with decreasing GA and was 5.2%  
189 among EP-infants and as high as 10% in infants born at 22-23 weeks gestation. Among EP-  
190 infants, the SNHI-prevalence was higher in boys than girls (6.2% vs 4.2%, p= 0.04), but there  
191 was no sex difference in SNHI-prevalence among VP- and MLP-infants (Supplementary  
192 Table 3). The SNHI-prevalence was similar in all three groups of preterm infants when  
193 comparing those born in the first (1999-2006) versus the second (2007-2014) 8-year epoch  
194 (Supplementary Table 4). The median (IQR) age at first-time diagnosis of SNHI was lower in  
195 EP-infants (1(0-4) year) and VP-infants EP-infants (1(0-4.5) year) compared to MLP- and  
196 term-born infants (4 (1-6) years), p < 0.002. The percentage distribution of age at first-time  
197 SNHI-diagnosis is displayed in Figure 1.

198 In the univariable, unadjusted analyses, intracranial haemorrhage was the only variable  
199 associated with increased risk of SNHI in the EP-infants (Table 2). Among the VP- and MLP-  
200 infants several variables, including delivery by caesarean section, SGA, intracranial  
201 haemorrhage and antibiotic therapy and mechanical ventilation, were associated with  
202 increased risk of SNHI (Table 2). For the VP- and MLP-infants we subsequently investigated  
203 the risk of SNHI in more “healthy” infants who neither received antibiotic therapy nor



204 mechanical ventilation. The SNHI-prevalence was then 1.6% in VP-infants and 1.0% in MLP-  
205 infants, which is still higher than a prevalence at 0.6 % in the term reference group, when  
206 excluding infants admitted to a NICU,  $p < 0.0001$ .

207 Table 3 displays crude and adjusted RRs for SNHI in all three groups of preterm  
208 infants. The crude RRs for SNHI increased from 1.7 (1.6-1.9) in MLP-infants, to 3.5 (3.0-4.1)  
209 in VP-infants and 7.9 (6.5-9.5) in EP-infants. After adjusting for SGA, the results remained  
210 similar. Figure 2 displays aRRs (95% CI) for SNHI in infants from 22 to 36 weeks GA. There  
211 was a steep increase in the risk of SNHI in the two most immature groups with aRRs at 11.8  
212 (9.0-15.3) for infants with GA 24-25 weeks and 14.8 (7.7-28.7) for infants with GA 22-23  
213 weeks.

214

## 215 **Discussion**

216 In this national cohort of more than 60 000 preterm infants, born between 1999 and 2014, and  
217 followed up through 2019, there was a significantly increased risk for SNHI in preterm  
218 compared to term infants, and the risk increased markedly in the most immature infants. In  
219 infants born after 28 weeks gestation, variables associated with increased perinatal morbidity,  
220 and in particular need for mechanical ventilation and antibiotic therapy, increased the risk for  
221 SNHI. In contrast, among the most immature infants only the presence of intracranial  
222 haemorrhage clearly increased the already high baseline risk of SNHI.

223 In our study the overall prevalence of SNHI among preterm infants was more than  
224 double that of the term reference group, but the risk for SNHI was around 15 times higher in  
225 the most immature babies. Several studies report higher rates of hearing impairment among  
226 preterm infants than in the general newborn population.<sup>6,23,25</sup> Most studies also demonstrate a  
227 similar clear trend, as in our study, with increasing rates of hearing impairment with  
228 decreasing GA<sup>5,7,25,26</sup> and BW.<sup>27,28</sup> Our prevalence results are in line with two recent large

229 studies from Poland and The Netherlands reporting hearing impairment rates ranging from 1-  
230 2% in preterm infants with GA 31-32 weeks and increasing to 7-11% in those with GA 24-25  
231 weeks.<sup>5,7</sup> However, rates of hearing impairment in preterm infants vary between studies due to  
232 variations in the diagnostic methods used and the definitions of hearing impairment.<sup>5,6,26-29</sup>  
233 SNHI-prevalence among EP-infants can also be affected by mortality rates of the sickest  
234 babies at highest risk for SNHI.<sup>6</sup> However, we found similar rates of SNHI in preterm infants  
235 born in the first and last 8-year epoch of our study cohort, concomitantly with stable survival  
236 rates for EP-infants in Norway during the same time period.<sup>30</sup> Two previous Norwegian  
237 historical cohort studies spanning from 1967 to 1998 also reported a 6-8-fold increased risk of  
238 hearing impairment in very low BW infants compared to normal weight term control  
239 infants.<sup>27,28</sup>

240 Sufficient follow-up time is important to detect progressive<sup>31</sup> and/or late-onset hearing  
241 impairment, which is reported in 13-33% of children with hearing impairment.<sup>32,33</sup> In contrast  
242 to previous reports<sup>16,34</sup>, we found no signs of increased risk for late-onset SNHI in our preterm  
243 cohort. In fact, the EP- and VP-infants were younger when a SNHI-diagnosis was established  
244 than more mature infants. This could also reflect raised awareness of possible adverse  
245 neurodevelopmental and hearing outcomes among preterm infants leading to closer follow-up  
246 of this population.<sup>35</sup>

247 In preterm infants many co-morbidities and therapies are identified as risk factors for  
248 hearing impairment.<sup>8,24,36,37</sup> The contribution of these risk factors to SNHI may differ,<sup>23</sup> but  
249 cumulative effects appear common.<sup>11,12</sup> The large UK Millennium Cohort Study reported an  
250 association between parental-reported neonatal illness and risk for hearing impairment in  
251 school age, but no association to GA.<sup>29</sup> In our study neonatal illness data were more detailed  
252 and we found different results. The pathophysiological pathways in hearing impairment  
253 associated with preterm birth are not well clarified. A central question is to what extent the

254 risk is associated with preterm birth itself or by its associated morbidity. The time before 27  
255 weeks of gestation is a critical period in auditory development with rapid growth of cochlea  
256 and the auditory nerve.<sup>38</sup> We speculate that SNHI in the most immature infants is causally  
257 linked to their immature auditory system, and that associated morbidities and invasive  
258 therapies have a relatively higher contribution in the causal pathways of SNHI in preterm  
259 infants with higher gestational age.<sup>12</sup> In the EP-infants, intracranial haemorrhage was the only  
260 independent risk factor for SNHI, an association also reported by others.<sup>39</sup> In contrast, among  
261 preterm infants born after 28 weeks gestation mechanical ventilation and antibiotic therapy  
262 were identified as strong independent predictors for SNHI, in line with many others.<sup>8,9,24,40</sup>  
263 Still, rates of SNHI remained significantly higher in VP- and MLP-infants not receiving these  
264 therapies when compared to term infants. Thus, overall our study indicates that that preterm  
265 birth across all GAs is an independent risk factor for SNHI.

266         Our study has several strengths. It covers a population-based cohort of more than  
267 60 000 preterm infants with data from several validated national health registries, including  
268 data on neonatal morbidity and treatment. The cohort spans the range from 22 to 36 weeks  
269 gestation, making it possible to assess differences in risk of SNHI across this range of  
270 prematurity. We used DAGs to select possible confounders for the regression analysis, but  
271 residual confounding cannot be excluded. The recorded SNHI diagnoses were established five  
272 years or longer after study participants were born, which made it possible to detect potentially  
273 late-onset cases of hearing impairment. As for similar cohort studies, several limitations also  
274 apply. First, we did not have data on treatment duration for mechanical ventilation and  
275 antibiotics, we lacked data on exposure to other drugs and noise, and we did not have  
276 information on SNHI in parents/siblings. Second, ICD-10 codes do not include criteria for  
277 hearing thresholds in decibel or affected frequencies and do therefore not assess the type or  
278 severity of SNHI. Procedural codes for hearing aids and cochlear implants would have

279 provide better data to assess functional loss of hearing impairment but were not available for  
280 this study. Third, the high rate of co-morbidities and invasive therapies in the relatively small  
281 group of EP-infants may have resulted in lack of statistical power to detect possible  
282 associations. Finally, preterm infants are also at increased risk for impaired central auditory  
283 processing function<sup>41</sup>, but such complex data were not available for this study.

284

## 285 **CONCLUSION**

286 Our study indicates that preterm birth is an independent risk factor for later SNHI. Invasive  
287 therapies and co-morbidities increased the risk for SNHI, but predominantly in preterm  
288 infants born after 28 weeks gestation. Infants born before 28 weeks gestation had high a risk  
289 for SNHI, and only the presence of intracranial haemorrhage increased the high baseline risk.

290

291

292

293 **ACKNOWLEDGMENTS**

294 We greatly appreciate the statistical advice from Professor Tom Wilsgaard, Department of  
295 Community Medicine, UiT-The Arctic University of Norway)

296

297 **Data sharing statement:** The study has utilized Norwegian governmental registries and legal  
298 restrictions do not permit the authors to share these data.

299

300 **Funding:** Support to this project was provided by the Northern Norway Regional Health  
301 Authority (grant number HN-1355-17), Gerda Meyer Nyquist Gulbrandson and Gerdt Meyer  
302 Nyquist's Fund, and the Norwegian SIDS and Stillbirth Society. The funders had no influence  
303 on the conduction of the research or writing this manuscript.

304

305 **Competing interest:** None

306

307 **Contributorship statement:** Dagny Hemmingsen conceptualized and designed the study, did  
308 the initial analysis, had full access to all the data in the study, takes responsibility for the  
309 integrity of the data and the accuracy of the data analysis, wrote the first draft of the  
310 manuscript, and revised the final manuscript. Dag Moster had a central role in acquisition of  
311 data, extracted and linked variables from the different data sources, took part in designing the  
312 study and writing of the manuscript. Bo Engdahl gave substantial contributions to the design  
313 of the work, took part in analysis of data and writing of the manuscript. Claus Klingenberg  
314 conceptualized and designed the study, supervised and coordinated data collection, gave  
315 directions in all phases of the study, had full access to all the data in the study, takes  
316 responsibility for the integrity of the data and the accuracy of the data analysis and revised the  
317 final manuscript. All authors approved the final manuscript to be published and agrees to be  
318 accountable for all aspects of the work.

319

320 **Ethics approval:** The study was performed in line with the principles of the Declaration of  
321 Helsinki. The study and linkage between the five registries were approved by the Regional  
322 Ethical Committee for medical and health research ethics (REK nr. 2018/1789).

323

324

325 **REFERENCES**

- 326 1. Moster D, Lie R, Markestad T. Long-Term Medical and Social Consequences of Preterm Birth.  
327 *N Engl J Med.* 2008;359(3):267-273. doi:10.1056/NEJMoa0706475
- 328 2. Dawes P, Newall J, Graham PL, Osmond C, Von Bonsdorff MB, Gunnar Eriksson J. Early Life  
329 Influences on Hearing in Adulthood: A Systematic Review and Two-Step Individual Patient  
330 Data Meta-Analysis. *Ear Hear.* 2022;43(3):722-732. doi:10.1097/AUD.0000000000001163
- 331 3. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. *Language of Early-and Later-Identified*  
332 *Children With Hearing Loss.* *Pediatrics* 1998; 102(5):1161-1171. doi:10.1542/peds.102.5.1161
- 333 4. Pimperton H, Kennedy CR. The impact of early identification of permanent childhood hearing  
334 impairment on speech and language outcomes. *Arch Dis Child.* 2012;97(7):648-653.  
335 doi:10.1136/archdischild-2011-301501
- 336 5. Wroblewska-Seniuk K, Greczka G, Dabrowski P, Szyfter-Harris J, Mazela J. Hearing  
337 impairment in premature newborns —Analysis based on the national hearing screening  
338 database in Poland. *PLoS One.* 2017;12(9):1-15. doi:10.1371/journal.pone.0184359
- 339 6. Robertson CMT, Howarth TM, Bork DLR, Dinu IA. Permanent bilateral sensory and neural  
340 hearing loss of children after neonatal intensive care because of extreme prematurity: A thirty-  
341 year study. *Pediatrics.* 2009;123(5). doi:10.1542/peds.2008-2531
- 342 7. Van Dommelen P, Verkerk PH, Van Straaten HLM, et al. Hearing loss by week of gestation and  
343 birth weight in very preterm neonates. *J Pediatr.* 2015;166(4):840-843.e1.  
344 doi:10.1016/j.jpeds.2014.12.041
- 345 8. Hille ETM, Van Straaten HLM, Verkerk PH, et al. Prevalence and independent risk factors for  
346 hearing loss in NICU infants. *Acta Paediatr.* 2007;96(8):1155-1158. doi:10.1111/j.1651-  
347 2227.2007.00398.x
- 348 9. Wang CH, Yang CY, Lien R, et al. Prevalence and independent risk factors for hearing  
349 impairment among very low birth weight infants. *Int J Pediatr Otorhinolaryngol.* 2017;93:123-  
350 127. doi:10.1016/j.ijporl.2016.12.029
- 351 10. Johnson S, Marlow N. Early and long-term outcome of infants born extremely preterm. *Arch*  
352 *Dis Child.* 2017;102(1):97-102. doi:10.1136/archdischild-2015-309581
- 353 11. Chant K, Bitner-Glindzicz M, Marlow N. Cumulative risk factors contributing to hearing loss  
354 in preterm infants. *Arch Dis Child Fetal Neonatal Ed.* 2023;108(5):464-470.  
355 doi:10.1136/archdischild-2022-324331
- 356 12. Marlow E, Hunt L, Marlow N. Sensorineural hearing loss and prematurity. *Arch Dis Child*  
357 *Fetal Neonatal Ed.* 2000;82:F141-F144. doi:10.1136/fn.82.2.f141
- 358 13. Calcutt TL, Dornan D, Beswick R, Tudehope DI. Newborn hearing screening in Queensland  
359 2009–2011: Comparison of hearing screening and diagnostic audiological assessment between  
360 term and preterm infants. *J Paediatr Child Health.* 2016;52(11):995-1003.  
361 doi:10.1111/jpc.13281
- 362 14. Thangavelu K, Martakis K, Feldmann S, Roth B, Lang-Roth R. Referral rate and false-positive  
363 rates in a hearing screening program among high-risk newborns. *Eur Arch Otorhinolaryngol.*  
364 2023;280(10):4455-4465. doi:10.1007/s00405-023-07978-y
- 365 15. van Noort-van der Spek IL, Goedegebure A, Hartwig NG, Kornelisse RF, Franken MCJP,  
366 Weisglas-Kuperus N. Normal neonatal hearing screening did not preclude sensorineural hearing

- 367 loss in two-year-old very preterm infants. *Acta Paediatr.* 2017;106(10):1569-1575.  
368 doi:10.1111/apa.13960
- 369 16. Savenko I V., Garbaruk ES, Krasovskaya EA. Changes in auditory function in premature  
370 children: A prospective cohort study. *Int J Pediatr Otorhinolaryngol.* 2020;139.  
371 doi:10.1016/j.ijporl.2020.110456
- 372 17. Aldè M, Di Berardino F, Ambrosetti U, et al. Hearing outcomes in preterm infants with  
373 confirmed hearing loss. *Int J Pediatr Otorhinolaryngol.* 2022;161.  
374 doi:10.1016/j.ijporl.2022.111262
- 375 18. Psarommatis I, Voudouris C, Kapetanakis I, Athanasiadi F, Douros K. Recovery of Abnormal  
376 ABR in Neonates and Infants at Risk of Hearing Loss. *Int J Otolaryngol.* 2017;2017:1-8.  
377 doi:10.1155/2017/7912127
- 378 19. Hof JR, Stokroos RJ, Wix E, Chenault M, Gelders E, Brokx J. Auditory maturation in  
379 premature infants: A potential pitfall for early cochlear implantation. *Laryngoscope.*  
380 2013;123(8):2013-2018. doi:10.1002/lary.24054
- 381 20. Irgens LM. The Medical Birth Registry of Norway. Epidemiological research and surveillance  
382 throughout 30 years. *Acta Obstet Gynecol Scand.* 2000;79(6):435-439. doi:10.1034/j.1600-  
383 0412.2000.079006435.x
- 384 21. Norwegian Institute of Public Health. Health Registries. Report.
- 385 22. Cain SE, Gomes T, Leisner D, et al. Clinical Guidance Document of Hearing in Infants and  
386 Young Children. American Academy of Audiology 2020.
- 387 23. Cristobal R, Oghalai JS. Hearing loss in children with very low birth weight: Current review of  
388 epidemiology and pathophysiology. *Arch Dis Child Fetal Neonatal Ed.* 2008;93(6).  
389 doi:10.1136/adc.2007.124214
- 390 24. Dumanch KA, Holte L, O'Hollearn T, Walker E, Clark J, Oleson J. High Risk Factors  
391 Associated With Early Childhood Hearing Loss: A 3-Year Review. *Am J Audiol.*  
392 2017;26(June):129142. doi:10.1044/2017\_AJA-16-0116
- 393 25. Vohr BR. Language and hearing outcomes of preterm infants. *Semin Perinatol.*  
394 2016;40(8):510-519. doi:10.1053/j.semperi.2016.09.003
- 395 26. Hirvonen M, Ojala R, Korhonen P, et al. Visual and hearing impairments after preterm birth.  
396 *Pediatrics.* 2018;142(2). doi:10.1542/peds.2017-3888
- 397 27. Engdahl B, Eskild A. Birthweight and the risk of childhood sensorineural hearing loss.  
398 *Paediatr Perinat Epidemiol.* 2007;21(6):495-500. doi:10.1111/j.1365-3016.2007.00844.x
- 399 28. Nafstad P, Samuelson SO, Irgens LM, Bjerkedal T. Birth Weight and Hearing Impairment in  
400 Norwegians Born From 1967 to 1993. *Pediatrics.* 2002;110(3):e30. doi:10.1542/peds.110.3.e30
- 401 29. Butcher E, Dezateux C, Knowles RL. Risk factors for permanent childhood hearing  
402 impairment. *Arch Dis Child.* 2020;105:187-189. doi:10.1136/archdischild-2018-315866
- 403 30. Stensvold HJ, Klingenberg C, Stoen R, et al. Neonatal morbidity and 1-year survival of  
404 extremely preterm infants. *Pediatrics.* 2017;139(3). doi:10.1542/peds.2016-1821
- 405 31. Barreira-Nielsen C, Fitzpatrick E, Hashem S, Whittingham JA, Barrowman N, Aglipay M.  
406 Progressive hearing loss in early childhood. *Ear Hear.* 2016;37(5):e311-e321.  
407 doi:10.1097/AUD.0000000000000325

- 408 32. Kataoka Y, Maeda Y, Fukushima K, et al. Prevalence and risk factors for delayed-onset hearing  
409 loss in early childhood: A population-based observational study in Okayama Prefecture, Japan.  
410 *Int J Pediatr Otorhinolaryngol.* 2020;138. doi:10.1016/j.ijporl.2020.110298
- 411 33. Watkin P, Baldwin M. The longitudinal follow up of a universal neonatal hearing screen: The  
412 implications for confirming deafness in childhood. *Int J Audiol.* 2012;51(7):519-528.  
413 doi:10.3109/14992027.2012.673237
- 414 34. van Noort-van der Spek IL, Goedegebure A, Hartwig NG, Kornelisse RF, Franken MCJP,  
415 Weisglas-Kuperus N. Normal neonatal hearing screening did not preclude sensorineural hearing  
416 loss in two-year-old very preterm infants. *Acta Paediatr.* 2017;106(10):1569-1575.  
417 doi:10.1111/apa.13960
- 418 35. Markestad T, Halvorsen B. National Guidelines for Developmental Follow-up of Children Born  
419 Preterm. The Norwegian Directorate of Health 2007.
- 420 36. van Dommelen P, Mohangoo a D, Verkerk PH, van der Ploeg CPB, van Straaten HLM. Risk  
421 indicators for hearing loss in infants treated in different neonatal intensive care units. *Acta*  
422 *Paediatr.* 2010;99(3):344-349. doi:10.1111/j.1651-2227.2009.01614.x
- 423 37. The Joint Committee on Infant Hearing. Year 2019 Position Statement: Principles and  
424 Guidelines for Early Hearing Detection and Intervention Programs. *The Journal of Early*  
425 *Hearing Detection and Intervention.* 2019;4(2):1-44. doi:10.1542/peds.106.4.798
- 426 38. Moore JK, Linthicum FH. The human auditory system: A timeline of development. *Int J*  
427 *Audiol.* 2007;46(9):460-478. doi:10.1080/14992020701383019
- 428 39. Bolisetty S, Dhawan A, Abdel-Latif M, et al. Intraventricular Hemorrhage and  
429 Neurodevelopmental Outcomes in Extreme Preterm Infants. *Pediatrics.* 2014;133(1):55-62.
- 430 40. Bielecki I, Horbulewicz A, Wolan T. Risk factors associated with hearing loss in infants: An  
431 analysis of 5282 referred neonates. *Int J Pediatr Otorhinolaryngol.* 2011;75(7):925-930.  
432 doi:10.1016/j.ijporl.2011.04.007
- 433 41. Amin SB, Orlando M, Monczynski C, Tillery K. Central auditory processing disorder profile in  
434 premature and term infants. *Am J Perinatol.* 2015;32(4):399-404. doi:10.1055/s-0034-1387928
- 435
- 436
- 437
- 438
- 439
- 440
- 441
- 442
- 443



444 **Figure Legends**

445

446 **Figure 1.** Age (years) at first-time diagnosis of sensorineural hearing impairment in preterm  
447 and term infants born in Norway 2008-2014 and alive at two years of age.

448 EP, extremely preterm; VP, very preterm; MLP, moderate-late preterm

449 Data based on NPR diagnoses which are available for infants from birth since 2008.

450

451

452

453 **Figure 2** Adjusted\* risk ratios (95% CI) for sensorineural hearing impairment according to  
454 weeks of gestation in preterm children born in Norway from 1999 through 2014.

455 \*Adjusted for SGA

456 Reference to term-born infants.

457

458

459

**Table 1.** Study cohort of infants born in Norway 1999-2014 and alive at two years of age - maternal and infant characteristics.

<b>Norwegian birth cohort 1999-2014</b>	GA 22 - 27 weeks N = 2 065	GA 28 - 31 weeks N = 6 192	GA 32 - 36 weeks N = 51 766	GA > 36 weeks N = 869 797
	<b>Extremely preterm infants</b>	<b>Very preterm infants</b>	<b>Moderate-late preterm infants</b>	<b>Term born Reference group</b>
<b>Maternal characteristics</b>				
Smoking at the beginning of pregnancy *	269 (13.0)	868 (14.0)	6 955 (16.2)	99 513 (11.4)
Low education (high school or less)	1 081 (52.3)	3 216 (51.9)	25 800 (49.8)	394 336 (45.2)
Parental consanguinity	21 (1.0)	64 (1.0)	541 (1.0)	9 053 (1.0)
Immigrant status of parents	298 (14.4)	735 (11.9)	5 811 (11.2)	106 651 (12.3)
Prolonged rupture (> 24 h) of membranes	402 (19.5)	1 045 (16.9)	6 779 (13.1)	50 938 (5.9)
Caesarean section	1 239 (59.6)	4 302 (69.5)	19 510 (37.7)	123 823 (14.2)
<b>Infant characteristics</b>				
Birth weight (g)	840 (770-990)	1 400 (1 180-1 625)	2 540 (2 185-2 880)	3 582 (3 260- 3915)
Birth length (cm)	34 (32-36)	40 (37-41)	46 (45-48)	50 (49-52)
Gestational age (weeks)	26 (25-27)	30 (29-31)	35 (34-36)	40 (39-41)
Small for gestational age	337 (16.3)	1 222 (19.7)	8 821 (17.0)	71 665 (8.2)
Male	1 068 (51.7)	3 297 (53.2)	27 196 (52.5)	445 643 (51.2)
Apgar 5-min score **	8 (6-9)	9 (8-9)	9 (9-9)	10 (9-10)
Apgar 5-min score categories				
0-3	99 (4.8)	98 (1.6)	257 (0.5)	1 477 (0.2)
4-6	510 (24.7)	585 (9.4)	1 295 (2.5)	6 359 (0.7)
7-10	1 398 (67.7)	5 453 (88.1)	50 058 (96.7)	761 700 (99.0)
Intracranial haemorrhage	533 (25.8)	492 (7.9)	280 (0.5)	606 (0.1)
Jaundice therapy	1 596 (77.3)	4 149 (67.0)	19 465 (37.6)	38 675 (4.4)
Antibiotic therapy	1 629 (78.9)	3 393 (54.8)	5 606 (10.8)	17 536 (2.0)
Non-invasive respiratory support	1 571 (76.1)	3 938 (63.6)	6 550 (12.7)	4 966 (0.6)
Mechanical ventilation	1 348 (65.3)	1 318 (21.3)	1 033 (2.0)	1 799 (0.2)
Admission to NICU	2 060 (99.8)	6 172 (99.7)	29 776 (57.5)	60 647 (7.3)
<b>Hearing Impairment</b>	108 (5.2)	143 (2.3)	597 (1.2)	5 794 (0.7)

All data are numbers and proportions (%) or median and interquartile range (IQR) if not otherwise stated.

GA, gestational age; NICU, neonatal intensive care admission. \*Data missing for 15.9% of mothers. \*\* Data missing for 0.2% of the total population,

**Table 2.** Univariable analysis and risk ratios (95 % CI) for sensorineural hearing impairment in preterm and term children born in Norway 1999-2014 (N=60 024)

	<b>Extremely preterm infants</b> GA 22 - 27 weeks N = 2 065	<b>Very preterm infants</b> GA 28 - 31 weeks N = 6 192	<b>Moderate-late preterm infants</b> GA 32 - 36 weeks N =51 766	<b>Term reference group</b> GA > 36 weeks N = 869 797
	RR (95 % CI)	RR (95 % CI)	RR (95 % CI)	RR (95 % CI)
Apgar 5 min score < 7 min	1.0 (0.7-1.5)	<b>1.6 (1.1-2.6)</b>	<b>3.1 (2.3-4.1)</b>	<b>2.3 (2.0-2.8)</b>
Small for gestational age	1.3 (0.8-2.1)	<b>1.6 (1.1-2.3)</b>	<b>1.6 (1.3-1.9)</b>	<b>1.5 (1.3-1.6)</b>
Caesarean section	0.8 (0.5-1.1)	<b>1.5 (1.03-2.25)</b>	<b>1.3 (1.1-1.5)</b>	<b>1.1 (1.1-1.2)</b>
Prolonged rupture of membranes	0.6 (0.3-1.0)	0.6 (0.4-1.0)	0.9 (0.7-1.1)	1.0 (0.9-1.1)
Intracranial haemorrhage	<b>2.0 (1.4-2.9)</b>	1.6 (0.95-2.57)	<b>4.7 (2.9-8.4)</b>	<b>4.2 (2.6-6.7)</b>
Antibiotic therapy	1.0 (0.6-1.6)	<b>1.7 (1.2-2.5)</b>	<b>2.1 (1.7-2.5)</b>	<b>2.5 (2.3-2.8)</b>
Non-invasive respiratory support	0.9 (0.6-1.4)	<b>1.4 (0.96-1.99)</b>	<b>1.5 (1.2-1.9)</b>	<b>3.5 (2.9-4.2)</b>
Mechanical ventilation	1.4 (0.9-2.1)	<b>2.4 (1.7-3.3)</b>	<b>5.0 (3.8-6.5)</b>	<b>6.0 (4.8-7.5)</b>
Jaundice therapy	0.8 (0.6-1.3)	1.2 (0.9-1.8)	<b>1.3 (1.1-1.5)</b>	<b>1.4 (1.3-1.6)</b>
Parental consanguinity	1.9 (0.5-7.0)	<b>3.5 (1.5-8.2)</b>	1.0 (0.4-2.1)	<b>1.8 (1.5-2.2)</b>

GA, gestational age; RR, risk ratio

**Table 3.** Prevalence, crude, and adjusted risk ratio (RR) for sensorineural hearing impairment in children born in Norway 1999 -2014 (N=60 024)

<b>Group description</b>	<b>Hearing impairment N (%)</b>	<b>Crude risk ratio (95 % CI)</b>	<b>Adjusted risk ratio* (95 % CI)</b>
<b>Term born, reference, GA &gt; 36 weeks.</b> N=869 797	5 749 (0.7)	Reference	Reference
<b>Moderate-late preterm infants, GA 32- 36 weeks</b> N=51 766	597 (1.2)	1.7 (1.6-1.9)	1.7 (1.5-1.8)
<b>Very preterm infants, GA 28-31 weeks</b> N=6 192	143 (2.3)	3.5 (3.0-4.1)	3.3 (2.8-3.9)
<b>Extremely preterm infants, GA 22-27 weeks</b> N=2 065	108 (5.2)	7.9 (6.5-9.5)	7.6 (6.3-9.1)

\* Adjusted for small for gestational age

GA, gestational age

Figure 1





Figure 2



**Suppl. Table 1.** Diagnostic codes for hearing impairment in ICD-10 and included cases from the Norwegian patient registry (NPR) and the Norwegian national insurance scheme (NIS).

<b>ICD-10 Diagnostic codes</b>		<b>Cases included from NPR*</b>	<b>Cases included from NIS**</b>	<b>Cases registered in both NPR and NIS</b>	<b>Total number of cases included.</b>
H 90.0	Conductive hearing loss, bilateral	No	No		
H 90.1	Conductive hearing loss, unilateral	No	No		
H 90.2	Conductive hearing loss, unspecified	No	No		
H 90.3	Sensorineural hearing loss, bilateral	Yes	Yes		
H 90.4	Sensorineural hearing loss, unilateral	Yes	Yes		
H 90.5	Sensorineural hearing loss, unspecified	Yes	Yes		
H 90.6	Mixed conductive and sensorineural hearing loss, bilateral	No	Yes		
H 90.7	Mixed conductive and sensorineural hearing loss, unilateral	No	Yes		
H 90.8	Mixed conductive and sensorineural hearing loss, unspecified	No	Yes		
H 91.3	Deaf mutism, not elsewhere classified	No	Yes		
H 91.8	Other specified hearing loss	No	Yes		
H 91.9	Hearing loss, unspecified	No	Yes		
<b>TOTAL</b>		5 339	433	363	5 409

**Suppl. Table 2.** Binomial regression analysis with interaction terms for antibiotics, mechanical ventilation, intracranial haemorrhage and jaundice. All Risk Ratio analyses are adjusted for small for gestational age.

Gestational age categories	Antibiotic treatment				Interaction term	P values
	YES	NO	YES	NO		
	Prevalence SNHI (%)	Prevalence SNHI (%)	Risk Ratios (95% CI)	Risk Ratios (95% CI)		
Reference (GA > 36 w)	287 (1.6)	5 507 (0.6)	1	1		
MLPI	119 (2.1)	478 (1.0)	1.26 (1.02-1.55)	1.50 (1.4-1.7)	1.23 (0.97-1.54)	0.085
VPI	97 (2.9)	46 (1.6)	1.66 (1.30-2.08)	2.40 (1.8-3.2)	1.46 (1.01-2.11)	<b>0.042</b>
EPI	85 (5.2)	23 (5.3)	3.08 (2.40-3.90)	7.90 (5.3-11.8)	2.56 (1.60-4.07)	<b>&lt; 0.001</b>
Gestational age categories	Mechanical ventilation				Interaction term	P values
	YES	NO	YES	NO		
	Prevalence SNHI (%)	Prevalence SNHI (%)	Risk Ratios (95% CI)	Risk Ratios (95% CI)		
Reference (GA > 36 w)	71 (3.9)	5 723 (0.7)	1	1		
MLPI	55 (5.3)	542 (1.1)	1.34 (0.95-1.89)	1.08 (1.05-1.10)	1.16 (0.81-1.66)	0.40
VPI	56 (4.2)	87 (1.8)	1.05 (0.74-1.48)	1.20 (1.13-1.31)	2.46 (1.65-3.69)	<b>&lt; 0.001</b>
EPI	78 (5.8)	30 (4.2)	1.46 (1.06-1.99)	1.70 (1.47-2.00)	4.23 (2.60-6.77)	<b>&lt; 0.001</b>
Gestational age categories	Intracranial haemorrhage				Interaction term	P values
	YES	NO	YES	NO		
	Prevalence SNHI (%)	Prevalence SNHI (%)	Risk Ratios (95% CI)	Risk Ratios (95% CI)		
Reference (GA > 36 w)	17 (2.8)	5 777 (0.7)	1	1		
MLPI	15 (5.4)	582 (1.1)	1.80 (0.91-3.55)	1.57 (1.44-1.71)	0.91 (0.46-1.80)	0.79
VPI	17 (3.5)	126 (2.2)	1.20 (0.62-2.32)	2.99 (2.52-3.56)	2.64 (1.33-5.23)	<b>0.005</b>
EPI	44 (8.3)	64 (4.2)	2.88 (1.67-4.98)	5.72 (4.50-7.28)	2.10 (1.16-3.82)	<b>0.015</b>
Gestational age categories	Jaundice				Interaction term	P values
	YES	NO	YES	NO		
	Prevalence SNHI (%)	Prevalence SNHI (%)	Risk Ratios (95% CI)	Risk Ratios (95% CI)		
Reference (GA > 36 w)	355 (0.9)	5 439 (0.7)	1	1		
MLPI	260 (1.3)	337 (1.0)	1.42 (1.21-1.67)	1.18 (1.09-1.27)	1.09 (0.89-1.32)	0.41
VPI	102 (2.5)	41 (2.0)	2.58 (2.08-3.21)	1.67 (1.30-2.13)	1.15 (0.79-1.67)	0.47
EPI	80 (5.0)	28 (6.0)	5.39 (4.26-6.84)	3.82 (2.74-5.32)	1.62 (1.05-2.50)	<b>0.03</b>

GA, gestational age; SNHI, sensorineural hearing impairment; w, weeks; EPI, Extremely preterm infants; VPI, Very preterm infants; MLPI, Moderate and late preterm infants



**Suppl. Table 3.** Sensorineural hearing impairment, divided by sex, in children born in Norway from 1999 through 2014


Group description	Gender distribution	MALE	FEMALE	Chi Square P-value	MALE	FEMALE
		Hearing impairment N %	Hearing impairment N (%)		Adjusted RR * (95% CI)	Adjusted RR * (95% CI)
<b>Reference group</b> GA > 36 weeks and not admitted N=869 797	Male: 51.2% (N=445 643)	3 021(0.7)	2 773 (0.7)		Not applicable	Not applicable
<b>Extremely preterm infants</b> GA 22-27 weeks N=2 065	Male: 51.7% (N=1 068)	66 (6.2)	42 (4.2)	4.03 <b>P= 0.045</b>	8.7 (6.9-11.1)	6.3 (4.7-8.4)
<b>Very preterm infants</b> GA 28-31 weeks N=6 192	Male: 53.2% (N=3 297)	72 (2.2)	71 (2.5)	0.49 P=0.48	3.1 (2.4-3.9)	3.7 (2.8-4.5)
<b>Moderate and late preterm infants</b> GA 32- 36 weeks N=51 766	Male: 52.5% (N=27 196)	337 (1.2)	260 (1.1)	3.7 P=0.054	1.8 (1.6-2.0)	1.5 (1.4-1.8)

\*Adjusted for small for gestational age

**Suppl. Table 4.** Comparison of sensorineural hearing impairment prevalence in the first and second 8-year epoch of the 16-year birth cohort


<b>Extremely preterm infants, &lt; 28 weeks gestation</b>	<b>N</b>	<b>Sensorineural hearing impairment N (%)</b>
<b>Birth year</b>		
1999-2006	1 072	54 (5.0%)
2007-2014	993	54 (5.4%)
Total cohort (1999-2014)	2 065	108 (5.2%)
<b>Very preterm infants, 28-31weeks gestation</b>	<b>N</b>	<b>Sensorineural hearing impairment N (%)</b>
<b>Birth year</b>		
1999-2006	3 175	69 (2.1%)
2007-2014	3 017	74 (2.5%)
Total cohort (1999-2014)	6 192	143 (2.3%)
<b>Extremely preterm infants, &lt; 28 weeks gestation</b>	<b>N</b>	<b>Sensorineural hearing impairment N (%)</b>
<b>Birth year</b>		
1999-2006	26 180	318 (1.2%)
2007-2014	25 586	279 (1.1%)
Total cohort (1999-2014)	51 766	579 (1.1%)

**Suppl. Figure 1.** Study cohort flow diagram.



BW, birth weight; GA, gestational age; ID, identification; NICU, Neonatal Intensive Care Unit,

Suppl. Figure 2. Directed acyclic graph on associations between preterm birth and hearing impairment.



BMI, Body Mass Index; BPD, bronchopulmonary dysplasia; C-section, caesarean section; NICU, Neonatal Intensive Care Unit  
 Dotted lines indicate an assumed causal relationship between mediators and the outcome.